MacroGenics, Inc. (MGNX) - יחס מחיר להכנסות חזויות

Biotech development depends on targeted therapy trial results, which determine the market split for MacroGenics, Inc. (MGNX). The forward P/S ratio reflects consensus dynamics, where the value 0.90 represents the current metric. Market capitalization relies on Margenza sales and royalties from oncology centers. Meanwhile, high R&D expenditures render operating profit volatile, despite having an approved drug.

Institutional capital utilizes this indicator to assess the overpayment for the future growth rates of MacroGenics, Inc. (MGNX) amid geopolitical risks affecting raw material supplies and patent protection. The expected P/S ratio is calculated as the ratio of current market capitalization to projected revenue, allowing an analysis of the chart to determine the fairness of the asset's market value relative to its potential cash flows.